MicroPort® Holds Groundbreaking Ceremony for R&D Building in Jiaxing MicroPort® Campus

Jiaxing, China, 22 March, 2021 - MicroPort Medical (Jiaxing) Co., Ltd recently held a groundbreaking ceremony for its R&D building at the Jiaxing MicroPort® Campus, located in Jiaxing Science and Technology City. During the ceremony, Glendy Wang, Chief Operating Officer of MicroPort® and Miao Zhu, Party Secretary of Jiaxing Nanhu District Committee, pushed the lever to symbolize the groundbreaking of the project.

The new R&D Building will cover a floor area of approximately 245,000 square meters, with the total floor area extending to 300,000 square meters post completion of the Campus. With these figures, the total headcount will reach around 5,000 employees, with production capacity increasing to several times the current level. This will ensure the company meets the demand for larger-scale productions in response to the implementation of the Medical Device Registrant System.

Yiyun Que, Senior Vice President of Supply Chain Business of MicroPort®, confirmed that, “Jiaxing MicroPort® Campus has been upholding MicroPort®’s philosophy of independent innovation and has demonstrated its commitment to developing pioneering products and modes of operation, responding to innovative systems, and leading high-quality development.”

Mr Panfeng Shao, Deputy Party Secretary of Nanhu District Committee and District Mayor of Nanhu District, Jiaxing, remarked, “Biomedicine is an important emerging industry in the Jiaxing Science and Technology City here in Nanhu District. With a deep-rooted presence in Jiaxing after years of development guided by the principle of innovation-driven and sound operation, MicroPort® has become a leading player in the field of biomedicine in the District. The Jiaxing Science and Technology City will continue to step up support for enterprises by backing incubation, encouraging R&D innovation, supporting the commercialization of research outcomes, and optimizing supporting services. It is our hope that MicroPort® will consider strategic expansion into more business areas in the future and continue to develop Jiaxing MicroPort® Campus into an industry-leading platform for high-end medical devices in China.”

As a world-leading medical group that delivers innovative and high-end medical devices, MicroPort® has established major production and R&D bases across the world, including Shanghai, Suzhou, Jiaxing and Shenzhen in China, Memphis in the USA, Paris, Milan, and in the Dominican Republic. Collaboratively, these bases work to ensure a solid global network of R&D, production, marketing and services.

Glendy Wang, Chief Operating Officer of MicroPort®, commented that, in the context of implementing the Yangtze River Delta Integration Strategy, MicroPort® will take full advantage of the strategic location of Jiaxing to mobilize resources from its surrounding cities of Shanghai, Suzhou and Jiaxing in an effort to introduce more operations into the Jiaxing MicroPort® Campus. In addition, MicroPort® will continue to develop an integrated platform for high-end medical devices to support the development of a market-oriented innovation system and industrial development model featuring industry-academia-research integration. Through this process, it aims to incubate more projects and companies and provide more quality integrated medical solutions for patients and doctors worldwide.

About MicroPort Medical (Jiaxing) Co., Ltd

MicroPort Medical (Jiaxing) Co., Ltd is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”, 00853.HK). With over 5,000 patents granted and more than 300 products marketed worldwide, MicroPort® has delivered products that not only fill gaps in the domestic market, but also widely used in over 10,000 hospitals across more than 80 countries and regions worldwide. On average, a MicroPort® product is used every six seconds across the world.

About Jianxing MicroPort® Campus

In 2015, Jianxing MicroPort® Campus was established as part of the Jiaxing Science and Technology City. Its subsidiaries include AccuPath Medical Technologies (Jiaxing) Co., Ltd., MicroPort Urocare (Jiaxing) Co., Ltd., MicroPort D-Pulse Medical (Jiaxing) Co., Ltd., Zhejiang Horizon Medical Technology Co., Ltd., and MicroPort Aesthetics (Jiaxing) Co., Ltd., which together employ close to 600 people, one-third of which are technical staff. Despite the impact of the COVID-19 pandemic in 2020, Jiaxing MicroPort® Campus achieved an increased output of nearly 40% compared to figures in 2019. To date, companies in the Campus have owned or filed applications for a total of 190 patents, including 115-patented inventions. Among these companies, AccuPath Medical Technologies (Jiaxing) Co., Ltd. (AccuPath Medical) has been accredited as “China high-tech enterprise” and “Zhejiang high-tech enterprise R&D center”.